FrancophonIA/ELRC3.0 huggingface dataset:
English: This medicine contains less than 1 mmol of sodium (23 mg) per 0.8 mL dose, i.e. essentially ‘sodiumfree'.
Slovenian: Zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 0,8 ml odmerek; to pomeni, da je praktično "brez natrija".
English: The patient alert card shall contain the following key messages:
Slovenian: Opozorilna kartica za bolnika mora vsebovati naslednje ključne točke:
English: SOLYMBIC treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which SOLYMBIC is indicated.
Slovenian: Zdravljenje z zdravilom SOLYMBIC mora uvesti in nadzorovati zdravnik specialist, izkušen v diagnosticiranju in zdravljenju bolezenskih stanj, za katere je zdravilo SOLYMBIC indicirano.
English: Maintenance of remission and response rates are presented in table 18.
Slovenian: Vzdrževanje remisije in deleže odziva prikazuje preglednica 18.
English: If you received SOLYMBIC during your pregnancy, your baby may have a higher risk for getting an infection.
Slovenian: Če ste prejemali zdravilo SOLYMBIC med nosečnostjo, obstaja večje tveganje, da bo vaš dojenček dobil okužbo.
English: If you have rheumatoid arthritis and you do not receive methotrexate with your SOLYMBIC therapy, your doctor may decide to give 40 mg every week.
Slovenian: Če imate revmatoidni artritis in hkrati z zdravilom SOLYMBIC ne dobivate metotreksata, vam bo zdravnik morda predpisal 40 mg vsak teden.
English: It is important that you tell your baby's doctors and other health care professionals about your SOLYMBIC use during your pregnancy so they can decide when your baby should receive any vaccine.
Slovenian: Zato je pomembno, da obvestite zdravnika vašega otroka in druge zdravstvene delavce, da ste med nosečnostjo prejemali zdravilo SOLYMBIC, da se lahko odločijo, kdaj bo vaš otrok lahko prejel katerokoli cepivo.
English: If active tuberculosis is diagnosed, SOLYMBIC therapy must not be initiated (see section 4.3).
Slovenian: Če se odkrije aktivna tuberkuloza, se zdravljenja z zdravilom SOLYMBIC ne sme začeti (glejte poglavje 4.3).
English: What you need to know before you use SOLYMBIC
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo SOLYMBIC
English: The European Medicines Agency has deferred the obligation to submit the results of the studies with adalimumab in one or more subsets of the paediatric population in ulcerative colitis and non-infectious uveitis, see section 4.2 for information on paediatric use.
Slovenian: Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z adalimumabom za eno ali več podskupin pediatrične populacije z ulceroznim kolitisom in neinfekcijskim uveitisom, za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2. 5.2 Farmakokinetične lastnosti
English: Thus additional caution should be exercised in considering SOLYMBIC treatment of these patients (see section 4.8).
Slovenian: Torej je potrebna dodatna previdnost, kadar razmišljamo o zdravljenju z zdravilom SOLYMBIC pri teh bolnikih (glejte poglavje 4.8).
English: It is not possible to administer SOLYMBIC to paediatric patients that require less than a full 20 mg or 40 mg dose.
Slovenian: Zdravila SOLYMBIC ni možno dati pediatričnim bolnikom, ki morajo prejeti manj kot polni 20 mg ali 40 mg odmerek.
English: Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of SOLYMBIC in patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.
Slovenian: O uporabi protituberkuloznega profilaktičnega zdravljenja se mora pred uvedbo zdravila SOLYMBIC razmisliti tudi pri bolnikih s hudimi ali pomembnimi faktorji tveganja za tuberkulozo kljub negativnemu testu za tuberkulozo in pri bolnikih z anamnezo latentne ali aktivne tuberkuloze, pri katerih ni mogoče potrditi ustreznega zdravljenja.
English: The conduct and results of these tests should be recorded on your Patient Alert Card.
Slovenian: Izvedbo in rezultate teh preiskav je treba zabeležiti na opozorilni kartici.
English: If you accidentally inject SOLYMBIC more frequently than told to by your doctor or pharmacist, you should call your doctor or pharmacist and tell him/her that you have taken more.
Slovenian: Če ste uporabili večji odmerek zdravila SOLYMBIC, kot bi smeli Če pomotoma injicirate zdravilo SOLYMBIC pogosteje, kot vam je naročil zdravnik ali farmacevt, se morate posvetovati z njim ali s farmacevtom in mu povedati, da ste uporabili večji odmerek.
English: Ophthalmologists are advised to consult with an appropriate specialist before initiation of treatment with SOLYMBIC (see section 4.4).
Slovenian: Oftalmologom se svetuje, da se pred začetkom zdravljenja z zdravilom SOLYMBIC posvetujejo z ustreznim specialistom (glejte poglavje 4.4).
English: Rates of discontinuation of corticosteroids or immunomodulators are presented in table 21.
Slovenian: Stopnja prenehanja zdravljenja s kortikosteroidi ali imunomodulatorji je predstavljena v preglednici 21.
English: As cases of tuberculosis have been reported in patients treated with adalimumab, your doctor will check you for signs and symptoms of tuberculosis before starting SOLYMBIC.
Slovenian: • Ker so bili pri bolnikih, zdravljenih z adalimumabom, opisani primeri tuberkuloze, vas bo zdravnik pred začetkom zdravljenja z zdravilom SOLYMBIC preiskal glede znakov in simptomov tuberkuloze.
English: PGA-F clear/minimal and ≥ 2-grade improvement a a
Slovenian: PGA-F čisto/minimalno in ≥ izboljšanje za dva razreda (%)
English: Following the administration of 24 mg/m
Slovenian: Po dajanju 24 mg/m
English: 95% confidence intervals for the differences in change scores between methotrexate and adalimumab c Based on rank analysis d
Slovenian: d ametotreksat 95% intervali zaupanja za razlike v spremembi ocen med metotreksatom in adalimumabom cna podlagi analize rangov zožitev sklepne špranje
English: Concomitant corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating treatment with SOLYMBIC.
Slovenian: Kortikosteroide, ki se jih daje sočasno, se lahko postopoma ukinja v skladu s klinično prakso, z začetkom dva tedna po začetku zdravljenja z zdravilom SOLYMBIC.
English: Figure 1: Kaplan-Meier curves summarising time to treatment failure on or after week 6 (study UV I) or week 2 (study UV II)
Slovenian: Slika 1: Kaplan-Meier-jeve krivulje povzemajo čas do neuspeha zdravljenja v ali po 6. tednu (študija UV I) ali 2. tednu (študija UV II)
English: Non-infectious uveitis affecting the back of the eye
Slovenian: Neinfekcijski uveitis, ki prizadene zadnji del očesa
English: If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis treatment before the initiation of SOLYMBIC, and in accordance with local recommendations.
Slovenian: Če se ugotovi latentna tuberkuloza, se mora pred uvedbo zdravila SOLYMBIC začeti s protituberkuloznim profilaktičnim zdravljenjem v skladu z lokalnimi priporočili.
English: At week 12, a significantly higher proportion of patients in study HS-II experienced a clinically relevant decrease in HS-related skin pain (see table 15).
Slovenian: V 12. tednu je statistično pomembno večji delež bolnikov v študiji HS-II občutil klinično pomembno zmanjšanje bolečine na koži, povezane s HS (glejte preglednico 15).
English: Detailed instructions for use are provided in the package leaflet.
Slovenian: Podrobna navodila za uporabo so navedena v navodilu za uporabo.
English: Patients on SOLYMBIC may receive concurrent vaccinations, except for live vaccines.
Slovenian: Bolniki, ki prejemajo zdravilo SOLYMBIC, lahko sočasno dobijo cepiva, razen živih cepiv.
English: Treatment with SOLYMBIC should not be initiated in patients with active infections including chronic or localised infections until infections are controlled.
Slovenian: Zdravljenja z zdravilom SOLYMBIC se ne sme začeti pri bolnikih z aktivnimi okužbami, vključno s kroničnimi ali lokaliziranimi, dokler te niso obvladane.
English: Certain vaccines may cause infections and should not be given while receiving SOLYMBIC.
Slovenian: • Določena cepiva lahko povzročijo okužbe, zato se jih med zdravljenjem z zdravilom SOLYMBIC ne sme uporabljati.
English: If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with SOLYMBIC and is positive for antibodies against double-stranded DNA, further treatment with SOLYMBIC should not be given (see section 4.8).
Slovenian: Če se bolniku po zdravljenju z zdravilom SOLYMBIC pojavijo simptomi, ki nakazujejo lupusu podobni sindrom, in ima pozitivna protitelesa proti dvojnoverižni DNA, zdravljenja z zdravilom SOLYMBIC ne sme nadaljevati (glejte poglavje 4.8).
English: It is not known whether SOLYMBIC passes into breast milk.
Slovenian: Ni znano, ali se zdravilo SOLYMBIC izloča v materinem mleku.
English: If you take SOLYMBIC the risk of getting lymphoma, leukaemia, or other cancers may increase.
Slovenian: Če uporabljate zdravilo SOLYMBIC, se vam lahko poveča tveganje za pojav limfoma, levkemije ali drugih vrst raka.
English: Week 52 Fistula remission
Slovenian: 52. teden Remisija fistule
English: The benefits and risks of continued weekly therapy should be carefully reconsidered in a patient with an inadequate response after the increase in dosing frequency (see section 5.1).
Slovenian: Koristi in tveganja nadaljevanja tedenskega zdravljenja je treba ponovno natančno pretehtati pri bolniku z nezadostnim odzivom na zdravljenje po povečanju pogostnosti odmerjanja (glejte poglavje 5.1).
English: However, because human immunoglobulins are excreted in milk, women must not breast-feed for at least five months after the last SOLYMBIC treatment.
Slovenian: Ker se človeški imunoglobulini izločajo v mleku, ženske ne smejo dojiti vsaj pet mesecev po zadnjem zdravljenju z zdravilom SOLYMBIC.
English: You should not take SOLYMBIC with medicines containing the active substance, anakinra or abatacept.
Slovenian: Zdravila SOLYMBIC ne smete jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept.
English: Table 23 Time to treatment failure in studies UV I and UV II
Slovenian: Čas do neuspeha zdravljenja v študijah UV I in UV II
English: SOLYMBIC is a biosimilar medicinal product.
Slovenian: Zdravilo SOLYMBIC je biološko podobno zdravilo.
English: • Relevant information on the safety concerns of serious infections, sepsis, tuberculosis and opportunistic infections; congestive heart failure; demyelinating disorders; malignancies to be addressed by the additional risk minimisation measures (e.g. seriousness, severity, frequency, time to onset, reversibility of the AE as applicable).
Slovenian: • Pomembne informacije o varnostnih zadržkih glede resnih okužb, sepse, tuberkuloze in oportunističnih okužb; kongestivnega srčnega popuščanja; demielinizirajoče bolezni; malignih bolezni, ki jih je treba obravnavati z dodatnimi ukrepi za zmanjševanje tveganja (npr. resnost, hudost, frekvenca, čas do pojava, reverzibilnost neželenih dogodkov, kot je primerno).
English: People with more serious rheumatoid arthritis that have had the disease for a long time may have a higher than average risk of getting lymphoma (a type of cancer that affects the lymph system), and leukaemia (a type of cancer that affects the blood and bone marrow).
Slovenian: Pri bolnikih z resnejšim revmatoidnim artritisom, ki imajo bolezen že dolgo, obstaja povečana verjetnost, da zbolijo za limfomom (vrsto raka, ki prizadene limfatični sistem) in levkemijo (vrsto raka, ki prizadene kri in kostni mozeg).
English: Patients should be tested for HBV infection before initiating treatment with SOLYMBIC.
Slovenian: Bolnike je treba pred začetkom zdravljenja z zdravilom SOLYMBIC testirati na okužbo s HBV.
English: Both studies demonstrated an early and sustained effect of adalimumab on the treatment failure rate versus placebo (see figure 1).
Slovenian: V obeh študijah je bil dokazan zgodnji in vzdrževan učinek adalimumaba na odstotek neuspeha zdravljenja proti placebu (glejte sliko 1).
English: Concomitant administration of SOLYMBIC with other biologic DMARDS (e.g. anakinra and abatacept) or other TNF-antagonists is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions (see section
Slovenian: Sočasna uporaba zdravila SOLYMBIC z drugimi biološkimi DMARDS (t.j.anakinra in abacept) ali z drugimi antagonisti TNF ni priporočljiva zaradi možnega povečanega tveganja za okužbe, vključno z resnimi okužbami, in drugih potencialnih farmakoloških interakcij (glejte poglavje 4.5).
English: In patients who develop HBV reactivation, SOLYMBIC should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.
Slovenian: Pri bolnikih, ki se jim pojavi reaktivacija HBV, je treba uporabo zdravila SOLYMBIC prekiniti in uvesti učinkovito protivirusno terapijo z ustreznim podpornim zdravljenjem.
English: Usually, SOLYMBIC is used with methotrexate.
Slovenian: Zdravilo SOLYMBIC ponavadi uporabljamo z metotreksatom.
English: If an anaphylactic reaction or other serious allergic reaction occurs, administration of SOLYMBIC should be discontinued immediately and appropriate therapy initiated.
Slovenian: Če se pojavi anafilaktična reakcija ali kakšna druga resna alergijska reakcija, je treba uporabo zdravila SOLYMBIC nemudoma prekiniti in uvesti ustrezno zdravljenje.
English: How to store SOLYMBIC Contents of the pack and other information
Slovenian: Shranjevanje zdravila SOLYMBIC Vsebina pakiranja in dodatne informacije
English: In non-infectious uveitis, corticosteroids or other medicines that influence the immune system may be continued while using SOLYMBIC.
Slovenian: V primeru neinfekcijskega uveitisa se kortikosteroidi ali druga zdravila, ki zavirajo imunski sistem, lahko še nadalje uporabljajo ob uporabi zdravila SOLYMBIC.
English: Children or adolescents with Crohn's disease
Slovenian: Otroci ali mladostniki s Crohnovo boleznijo
English: SOLYMBIC may have a minor influence on your ability to drive, cycle or use machines.
Slovenian: Zdravilo SOLYMBIC ima lahko blag vpliv na sposobnost vožnje, kolesarjenja ali upravljanja s stroji.
English: Therefore, the combination of SOLYMBIC and anakinra is not recommended (see section 4.5).
Slovenian: Zato kombinacija zdravila SOLYMBIC in anakinre ni priporočljiva (glejte poglavje 4.5).
English: Mood alterations (including depression), Anxiety,
Slovenian: Psihiatrične motnje spremembe razpoloženja (vključno z depresijo), anksioznost, nespečnost
English: If you are about to undergo surgery or dental procedures please inform your doctor that you are taking SOLYMBIC.
Slovenian: • Če boste imeli kirurški poseg ali poseg na zobeh, prosimo, povejte svojemu zdravniku, da jemljete zdravilo SOLYMBIC.
English: If adequate response is achieved with an increased dosing frequency, the dose may subsequently be reduced to 40 mg every other week.
Slovenian: Če je dosežen zadosten odziv na zdravljenje s povečano pogostnostjo odmerjanja, se lahko odmerek pozneje zmanjša na 40 mg vsak drugi teden.
English: If you have an infection, including long-term or localised infection (for example, leg ulcer) consult your doctor before starting SOLYMBIC.
Slovenian: • Če imate kakšno okužbo, vključno z dolgotrajno ali omejeno okužbo (npr. razjedo na nogi), se pred uporabo zdravila SOLYMBIC posvetujte s svojim zdravnikom.
English: Table 9 Efficacy response in placebo-controlled axial SpA study
Slovenian: Odziv učinkovitosti v s placebom kontrolirani Axial SpA študiji
English: Before you use a SOLYMBIC pre-filled syringe, read this important information:
Slovenian: Pred uporabo napolnjene injekcijske brizge zdravila SOLYMBIC preberite te pomembne informacije:
English: Clinical remission Clinical response (CR-100) Patients in steroid-free remission for > = 90 days a
Slovenian: Klinična remisija Klinični odziv (CR-100) Bolniki v remisiji brez steroidov za ≥ 90 dni a
English: Patients treated with SOLYMBIC should be given the special alert card.
Slovenian: Bolniki, ki se zdravijo z zdravilom SOLYMBIC, morajo dobiti opozorilno kartico za bolnike.
English: Alternatively, if a patient has stopped SOLYMBIC and signs and symptoms of disease recur, SOLYMBIC may be re-administered.
Slovenian: Če bolnik neha uporabljati zdravilo SOLYMBIC, pa se znaki in simptomi bolezni ponovijo, je mogoče zdravilo SOLYMBIC znova uvesti.
English: Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (See table 23).
Slovenian: Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali adalimumab, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 23).
English: Patients must therefore be monitored closely for infections, including tuberculosis, before, during and after treatment with SOLYMBIC.
Slovenian: Bolnike je zato treba pred, med in po zdravljenju z zdravilom SOLYMBIC natančno kontrolirati glede okužb, vključno s tuberkulozo.
English: What SOLYMBIC is and what it is used for What you need to know before you use SOLYMBIC How to use SOLYMBIC
Slovenian: Kaj je zdravilo SOLYMBIC in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo SOLYMBIC Kako uporabljati zdravilo SOLYMBIC Možni neželeni učinki
English: Table 8 Efficacy responses in placebo-controlled AS study - study I reduction of signs and symptoms
Slovenian: Odzivi učinkovitosti v študiji pri ankilozirajočem spondilitisu, kontrolirani s placebom - študija I zmanjšanje znakov in simptomov
English: Keep SOLYMBIC in the outer carton in order to protect from light.
Slovenian: Zdravilo SOLYMBIC shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
English: SOLYMBIC is used to treat Crohn's disease in adults and children aged 6 to 17 years.
Slovenian: Zdravilo SOLYMBIC se uporablja za zdravljenje Crohnove bolezni pri odraslih in otrocih, starih 6 do 17 let.
English: Greater improvements at week 12 from baseline compared to placebo were demonstrated in skinspecific health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I and HS-II), patient global satisfaction with medication treatment as measured by the Treatment Satisfaction Questionnaire-medication (TSQM; Studies HS-I and HS-II), and physical health as measured by the physical component summary score of the SF-36 (study HS-I).
Slovenian: Večje izboljšanje v 12. tednu so pokazali glede na izhodiščno vrednost v primerjavi s placebom glede z zdravjem povezane kakovosti življenja, specifične za kožo, merjene z dermatološkim indeksom kakovosti življenja (“Dermatology life quality index” (DLQI), v študijah HS-I in HS-II), glede bolnikovega splošnega zadovoljstva z zdravljenjem z zdravilom, merjenem z vprašalnikom o zadovoljstvu z zdravljenjem z zdravilom (“Treatment Satisfaction Questionnaire - medication” (TSQM), v študijah HS-I in HS-II), in glede telesnega zdravja, merjenega s seštevkom telesnih komponent v vprašalniku SF-36 (“Short Form Health Survey" (SF 36) v študiji HS-I).
English: The volume for injection is selected based on the patients' height and weight (table 1).
Slovenian: Volumen za injiciranje se določi glede na bolnikovo višino in telesno maso (glejte preglednico 1).
English: Treatment with SOLYMBIC may result in the formation of autoimmune antibodies.
Slovenian: Zdravljenje z zdravilom SOLYMBIC lahko povzroči nastanek avtoimunskih protiteles.
English: In psoriasis studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 response from baseline at week 16 (see tables 11 and 12).
Slovenian: V študijah pri psoriazi I in II je bil primarna končna točka delež bolnikov, ki so od izhodišča do 16. tedna dosegli PASI 75 (glejte preglednici 11 in 12).
English: During treatment with SOLYMBIC, other concomitant therapies (e.g. corticosteroids and/or immunomodulatory agents) should be optimised.
Slovenian: Med zdravljenjem z zdravilom SOLYMBIC je treba optimizirati druge sočasne terapije (npr. kortikosteroide in/ali imunomodulacijska zdravila).
English: Nail psoriasis assessments included the Modified Nail Psoriasis Severity Index (mNAPSI), the Physician's Global Assessment of Fingernail Psoriasis (PGA-F) and the Nail Psoriasis Severity Index (NAPSI) (see table 13).
Slovenian: Ocena psoriaze nohtov je vključevala prilagojeni indeks izrazitosti psoriaze nohtov (mNAPSI - Modified Nail Psoriasis Severity Index), zdravnikovo globalno oceno psoriaze nohtov (PGA-F - Physician's Global Assessment of Fingernail Psoriasis) in indeks izrazitosti psoriaze nohtov (NAPSI - Nail Psoriasis Severity Index) (glejte preglednico 13).
English: SOLYMBIC works by reducing this inflammation.
Slovenian: Zdravilo SOLYMBIC deluje tako, da zmanjša tako vnetje.
English: 1 p value for standard dose versus low dose comparison Immunosuppressant therapy could only be discontinued at or after week 26 at the investigator's discretion if the subject met the clinical response criterion defined as a closure of all fistulas that were draining at baseline for at least 2 consecutive post-baseline visits
Slovenian: 1p vrednost za primerjavo standardnega odmerka proti majhnemu odmerku 2Zdravljenje z imunosupresivi je bilo lahko prekinjeno v 26. tednu ali po njem po raziskovalčevi diskreciji, če je bolnik izpolnjeval kriterije kliničnega odziva 3definiran kot zaprtje vseh fistul, ki so bile prisotne ob začetku študije na vsaj 2 zaporednih obiskih po začetku
English: Patients who develop a new infection while undergoing treatment with SOLYMBIC, should be monitored closely and undergo a complete diagnostic evaluation.
Slovenian: Bolnike, pri katerih se med zdravljenjem z zdravilom SOLYMBIC pojavi nova okužba, je treba natančno nadzirati in opraviti morajo popolno diagnostično obravnavo.
English: SOLYMBIC is also used to treat severe plaque psoriasis in children and adolescents weighing either 23 to 28 kg or 47 kg or greater for whom topical therapy and phototherapies have either not worked very well or are not suitable.
Slovenian: Zdravilo SOLYMBIC se uporablja tudi za zdravljenje hude luskavice v plakih pri otrocih in mladostnikih, ki tehtajo ali od 23 do 28 kg ali 47 kg ali več, pri katerih lokalno zdravljenje in zdravljenja s svetlobo nista dovolj dobro delovala ali pa nista primerna.
English: SOLYMBIC can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment.
Slovenian: Zdravilo SOLYMBIC je mogoče uporabljati tudi za zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa brez predhodnega zdravljenja z metotreksatom.
English: In rheumatoid arthritis, methotrexate is continued while using SOLYMBIC.
Slovenian: Pri revmatoidnem artritisu se uporaba metotreksata med uporabo zdravila SOLYMBIC nadaljuje.
English: For subcutaneous use.
Slovenian: Subkutana uporaba.
English: After proper training in injection technique, patients may self-inject with SOLYMBIC if their physician determines that it is appropriate and with medical follow-up as necessary.
Slovenian: Bolniki, ki se naučijo pravilnega postopka injiciranja, si zdravilo SOLYMBIC lahko injicirajo sami, če zdravnik presodi, da je to primerno, in je zagotovljeno ustrezno medicinsko spremljanje.
English: Two weeks later (day 29) continue with a dose of 40 mg every week.
Slovenian: Čez dva tedna (29. dan) nadaljujte z odmerkom 40 mg vsak teden.
English: Among patients who were at least partial responders at week 12, and who received continuous weekly adalimumab therapy, the HiSCR rate at week 48 was 68.3% and at week 96 was 65.1%.
Slovenian: Med bolniki, ki z vsaj delnim odzivom v 12. tednu, in ki so prejemali neprekinjeno tedensko terapijo z adalimumabom vsak teden, je bila stopnja kliničnega odziva (HiSCR) v 48. tednu 68,3 % in v 96. tednu 65,1 %.
English: Some of those patients were also treated with azathioprine or 6-mercaptopurine.
Slovenian: Nekateri od teh bolnikov so bili zdravljeni tudi z azatioprinom ali 6-merkaptopurinom.